Top Page
Intelligent Bio Solutions
(NASDAQ:INBS)
Intelligent Bio Solutions (INBS) vs. SPDR S&P 500 ETF (SPY)
Intelligent Bio Solutions Business Overview & Revenue Model
Intelligent Bio Solutions Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.29M | 3.05M | 3.11M | 1.26M | 0.00 | 1.98M |
| Gross Profit | 1.42M | 1.25M | 1.43M | 326.67K | 0.00 | 1.98M |
| EBITDA | -9.64M | -9.45M | -9.31M | -9.47M | -8.33M | 0.00 |
| Net Income | -10.87M | -10.57M | -10.16M | -10.63M | -8.31M | -7.04M |
Balance Sheet | ||||||
| Total Assets | 10.04M | 8.25M | 13.78M | 10.35M | 12.35M | 21.86M |
| Cash, Cash Equivalents and Short-Term Investments | 1.66M | 1.02M | 6.30M | 1.54M | 8.28M | 12.57M |
| Total Debt | 1.95M | 281.81K | 1.15M | 1.92M | 0.00 | 0.00 |
| Total Liabilities | 6.61M | 5.44M | 5.60M | 6.67M | 5.81M | 6.85M |
| Stockholders Equity | 3.62M | 3.00M | 8.33M | 3.80M | 6.62M | 15.06M |
Cash Flow | ||||||
| Free Cash Flow | -10.44M | -9.91M | -9.79M | -7.88M | -3.74M | -11.30M |
| Operating Cash Flow | -10.14M | -9.68M | -9.57M | -7.38M | -3.36M | -11.30M |
| Investing Cash Flow | -302.24K | -231.84K | -221.43K | -694.14K | -880.22K | 0.00 |
| Financing Cash Flow | 8.11M | 4.60M | 14.56M | 1.44M | 0.00 | 23.40M |
Intelligent Bio Solutions Technical Analysis
Intelligent Bio Solutions Risk Analysis
Intelligent Bio Solutions Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $9.78M | ― | ― | ― | ― | ― | |
46 Neutral | $8.46M | -0.41 | -223.45% | ― | 3.26% | 65.96% | |
45 Neutral | $3.85M | -0.04 | -245.18% | ― | -27.66% | 13.18% | |
41 Neutral | $3.40M | -0.04 | -296.20% | ― | -67.73% | 58.35% |
Intelligent Bio Solutions Corporate Events
On January 28, 2026, Intelligent Bio Solutions announced it has begun a new clinical study program to support an FDA 510(k) submission for U.S. market clearance of its non-invasive Intelligent Fingerprinting Drug Screening System for detecting the opiate codeine. Working with clinical research organization Cliantha Research, the company is running an initial study in 40 adults using its cartridge and DSR-Plus reader, comparing performance with an existing FDA-cleared predicate device and confirming results via LC-MS/MS, with the first cohort starting the same day and full data analysis expected by the end of March 2026. The resulting data will be folded into an FDA submission aimed at moving the product beyond “Forensic Use Only” status and into broader U.S. commercial use, positioning the company to tap into the multi-billion-dollar U.S. drug screening market and potentially strengthening its competitive standing in workplace, clinical, and law-enforcement testing segments.
The most recent analyst rating on (INBS) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
On January 7, 2026, Intelligent Bio Solutions Inc. announced that it had regained compliance with Nasdaq’s minimum bid price requirement after previously falling out of compliance when its common stock traded below $1.00 per share for 30 consecutive business days leading up to a deficiency notice dated December 16, 2025. The company’s return to compliance, achieved by maintaining a closing bid price of at least $1.00 for 14 consecutive business days from December 16, 2025, to January 6, 2026, removes the immediate risk of delisting from the Nasdaq Capital Market and closes the matter with the exchange’s listing qualifications staff.
The most recent analyst rating on (INBS) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
On December 31, 2025, Intelligent Bio Solutions entered into a securities purchase agreement with healthcare-focused institutional investors for a private placement of 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof) together with Series K-1 and Series K-2 warrants, at a combined purchase price of $4.35, generating approximately $10.0 million in gross proceeds; the transaction, priced at-the-market under Nasdaq rules, closed on January 2, 2026, with 105,000 shares and 2,193,850 pre-funded warrants issued, taking the company’s outstanding common stock to 1,216,142 shares. The warrants are immediately exercisable, with pre-funded warrants priced at $0.01 per share and Series K-1 and K-2 warrants at $4.10 per share for a five-year term following effectiveness of a registration statement, while the company has committed to register the resale of the shares and warrant shares and plans to use the net proceeds for working capital and general corporate purposes, bolstering its balance sheet and providing additional funding flexibility as it pursues growth in the non-invasive drug testing market; Ladenburg Thalmann acted as exclusive placement agent under a fee and expense arrangement tied to the offering and any future warrant exercises.
The most recent analyst rating on (INBS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
On December 31, 2025, Intelligent Bio Solutions announced a strategic manufacturing partnership with Syrma Johari MedTech to support and scale production of its Intelligent Fingerprinting Drug Screening Reader, a move aimed at strengthening global production capacity and improving profitability. Under the new arrangement, the company expects annual production cost savings of more than 40%, translating into an anticipated improvement of about 20 percentage points in gross margin compared with its previous manufacturing setup, while gaining access to manufacturing capacity roughly four times its current level. The deal diversifies INBS’s supplier base, bolsters supply-chain resilience and aligns with its global expansion plans, including a planned U.S. market entry in 2026, by leveraging Syrma Johari’s extensive, certified medical device manufacturing footprint across India, Europe and the United States and its regulatory and quality-assurance expertise across major jurisdictions.
The most recent analyst rating on (INBS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
On December 15, 2025, Intelligent Bio Solutions Inc. received a deficiency letter from Nasdaq due to its stock price falling below $1.00 for 30 consecutive business days, failing to meet the minimum bid price requirement for continued listing. The company has until June 15, 2026, to regain compliance, and has initiated a 1-for-10 reverse stock split to address this issue, effective December 15, 2025, with trading on a split-adjusted basis starting December 16, 2025.
The most recent analyst rating on (INBS) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
On October 16, 2025, Intelligent Bio Solutions Inc. held its annual stockholder meeting where an amendment was approved to effect a reverse stock split. The company’s board decided on a 1-for-10 reverse stock split, which was filed on December 12, 2025, and became effective on December 15, 2025. This move reduced the number of outstanding shares from approximately 9.6 million to 960,000, with trading on a split-adjusted basis beginning on December 16, 2025. The reverse stock split aims to consolidate shares without altering the overall equity structure, except for cash payments in lieu of fractional shares.
The most recent analyst rating on (INBS) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
Intelligent Bio Solutions Inc. provided a presentation to investors on December 2, 2025, detailing aspects of its business and operations. The presentation is available on the company’s website, and the information is furnished under Regulation FD, not filed under the Securities Exchange Act of 1934.
The most recent analyst rating on (INBS) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
On November 25, 2025, Intelligent Bio Solutions Inc. issued 75,000 restricted shares of common stock to MDM Worldwide Solutions, Inc. as equity compensation for strategic communication advisory and consulting services. This issuance, exempt from registration under the Securities Act, reflects the company’s strategic move to enhance its communication capabilities without cash transactions.
The most recent analyst rating on (INBS) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.